Trials / Completed
CompletedNCT00894660
A Bioequivalence Study Comparing Amodiaquine Tablet (Pfizer) To Amodiaquine Tablets (Arsuamoon-Guilin China) In Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 38 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 21 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The study will determine if amodiaquine tablet (Pfizer), an antimalaria agent, is pharmaceutically equivalent to a comparator product (Arsuamoon-Guilin China).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Amodiaquine (Test) | Oral tablet, single dose, 1 X 300 MG |
| DRUG | Amodiaquine (Comparator) | Oral tablet, single dose, 2 X 150 MG |
Timeline
- Start date
- 2009-06-01
- Primary completion
- 2009-07-01
- Completion
- 2009-07-01
- First posted
- 2009-05-07
- Last updated
- 2010-04-21
Locations
1 site across 1 country: Singapore
Source: ClinicalTrials.gov record NCT00894660. Inclusion in this directory is not an endorsement.